Ambrx

Ambrx

Biotechnology, N Torrey Pines Rd, San Diego, , 92037, California, 10975, United States, 51-200 Employees

ambrx.com

  • facebook
  • LinkedIn

phone no Phone Number: 85********

Who is AMBRX

Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADC...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from AMBRX

Ambrx Org Chart and Mapping

Employees

Jiaqi Ran

General Ledger Accountant

Alicia Menendez

Senior Research Associate

Nick Knudsen

Process and Development Associate II

Mingchao Kang

Group Lead, Head of Technology Platform

Shannon Ryan

Sr. Executive Assistant

Ying Sun

Associate Director of Chemistry

Mark Janis

VP, Corporate Controller

Similar Companies to Ambrx

Aiolos Bio

  • 11-50 11-50
  • 1 Billion and Over $ 1 Billion and Over

aTyr Pharma

  • 11-50 11-50
  • 25 Million to 50 Million $ 25 Million to 50 Million

Cytokinetics

  • 201-500 201-500
  • 50 Million to 100 Million $ 50 Million to 100 Million
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Ambrx

Answer: Ambrx's headquarters are located at N Torrey Pines Rd, San Diego, , 92037, California, 10975, United States

Answer: Ambrx's phone number is 85********

Answer: Ambrx's official website is https://ambrx.com

Answer: Ambrx's revenue is $1 Million to $5 Million

Answer: Ambrx's SIC: 2834

Answer: Ambrx has 51-200 employees

Answer: Ambrx is in Biotechnology

Answer: Ambrx top competitors include: Aiolos Bio , aTyr Pharma , Cytokinetics

Answer: Ambrx contact info: Phone number: 85******** Website: https://ambrx.com

Answer: Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrxs protein engineering technology.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access